Bioxcel Therapeutics Stock Investor Sentiment

BTAI Stock  USD 0.43  0.02  4.88%   
Under 58% of all BioXcel Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that some traders are interested. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
  

BioXcel Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at www.macroaxis.com         
Disposition of 521 shares by Oneill Vincent of BioXcel Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Acquisition by Mueller Peter of 17000 shares of BioXcel Therapeutics at 1.44 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
BioXcel Therapeutics Given Buy Rating at Canaccord Genuity Group - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evalua...
Yahoo News
over three months ago at benzinga.com         
BioXcel Therapeutics Approved Drug For Bipolar DisordersSchizophrenia Shows No Evidence Of Worsening...
benzinga news
over three months ago at news.google.com         
59514 Shares in BioXcel Therapeutics, Inc. Purchased by Virtu Financial LLC - Defense World
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 2134 shares by Vimal Mehta of BioXcel Therapeutics at 1.2835 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 3500 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 2609 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
BioXcel Therapeutics doubles authorized shares By Investing.com - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Bray June of 17000 shares of BioXcel Therapeutics at 1.44 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
BioXcel Therapeutics, Inc. Given Average Rating of Hold by Brokerages - MarketBeat
Google News at Macroaxis
over three months ago at investing.com         
Bioxcel therapeutics CEO sells shares worth over 405,000
Investing News at Macroaxis
over three months ago at investing.com         
Disposition of 2609 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Investing News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 126014 shares by Vimal Mehta of BioXcel Therapeutics at 1.6309 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.

BioXcel Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Matthew Wiley of 750 shares of BioXcel Therapeutics subject to Rule 16b-3
09/13/2024
2
Disposition of 215 shares by Matthew Wiley of BioXcel Therapeutics at 0.6908 subject to Rule 16b-3
09/16/2024
3
Mizuho maintains Neutral rating on BioXcel Therapeutics stock - Investing.com
09/23/2024
4
Disposition of 2610 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
09/26/2024
5
Disposition of 5556 shares by Oneill Vincent of BioXcel Therapeutics at 0.55 subject to Rule 16b-3
10/03/2024
6
BioXcel Therapeutics CSO sells shares worth 3,946
10/04/2024
7
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 for Treating Acute Stress Disorder
10/15/2024
8
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
11/08/2024
9
BioXcel Therapeutics Inc Reports Q3 2024 Earnings Net Revenue at 214K, Net Loss Narrows to 13.7M
11/14/2024
10
BioXcel Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Trials and ...
11/15/2024
11
BioXcel Therapeutics amends credit agreement, issues new warrants
11/21/2024
12
BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering
11/22/2024

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.